Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

99,682 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification and optimization of anthranilic sulfonamides as novel, selective cholecystokinin-2 receptor antagonists.
Allison BD, Phuong VK, McAtee LC, Rosen M, Morton M, Prendergast C, Barrett T, Lagaud G, Freedman J, Li L, Wu X, Venkatesan H, Pippel M, Woods C, Rizzolio MC, Hack M, Hoey K, Deng X, King C, Shankley NP, Rabinowitz MH. Allison BD, et al. Among authors: li l. J Med Chem. 2006 Oct 19;49(21):6371-90. doi: 10.1021/jm060590x. J Med Chem. 2006. PMID: 17034143
Discovery of potent cholecystokinin-2 receptor antagonists: elucidation of key pharmacophore elements by X-ray crystallographic and NMR conformational analysis.
Rosen MD, Hack MD, Allison BD, Phuong VK, Woods CR, Morton MF, Prendergast CE, Barrett TD, Schubert C, Li L, Wu X, Wu J, Freedman JM, Shankley NP, Rabinowitz MH. Rosen MD, et al. Among authors: li l. Bioorg Med Chem. 2008 Apr 1;16(7):3917-25. doi: 10.1016/j.bmc.2008.01.059. Epub 2008 Feb 5. Bioorg Med Chem. 2008. PMID: 18289861
JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability.
Morton MF, Barrett TD, Freedman J, Li L, Rizzolio MC, Prendergast CE, Wu X, Moreno V, Pyati J, Figueroa K, Cagnon L, Lagaud G, Ver Donck L, Ghoos E, Allison B, Rabinowitz MH, Shankley NP. Morton MF, et al. Among authors: li l. J Pharmacol Exp Ther. 2011 Jul;338(1):328-36. doi: 10.1124/jpet.110.178483. Epub 2011 Apr 14. J Pharmacol Exp Ther. 2011. PMID: 21493750
3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a novel, potent, and selective cholecystokinin 1 receptor antagonist: in vitro and in vivo pharmacological comparison with dexloxiglumide.
Morton MF, Barrett TD, Yan W, Freedman JM, Lagaud G, Prendergast CE, Moreno V, Pyati J, Figueroa K, Li L, Wu X, Rizzolio M, Breitenbucher JG, McClure K, Shankley NP. Morton MF, et al. Among authors: li l. J Pharmacol Exp Ther. 2007 Nov;323(2):562-9. doi: 10.1124/jpet.107.124578. Epub 2007 Aug 7. J Pharmacol Exp Ther. 2007. PMID: 17684117
SAR studies of 1,5-diarylpyrazole-based CCK1 receptor antagonists.
Gomez L, Hack MD, McClure K, Sehon C, Huang L, Morton M, Li L, Barrett TD, Shankley N, Breitenbucher JG. Gomez L, et al. Among authors: li l. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6493-8. doi: 10.1016/j.bmcl.2007.09.093. Epub 2007 Oct 1. Bioorg Med Chem Lett. 2007. PMID: 17933530
99,682 results
You have reached the last available page of results. Please see the User Guide for more information.